SavedAdd your journal

Journals / Ağrı / 2020 / Cilt: 32 - Sayı: 2

Ağrılı diyabetik periferal nöropatide dolu bardak testi ile ağrı şiddetinin belirlenmesi

Detecting pain severity with full cup test in painful diabetic peripheral neuropathy

Bahar SAY
Ufuk ERGÜN
Ayşe YILDIZ
Murat ALPUA
Şenay DURMAZ ARIKAN
Ebru TURGAL
Journal
Ağrı
Pages
85–90
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Sonuç: Dolu bardak testi ADPN’de ağrı şiddetini belirlemede kullanışlı olabilir.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Amaç: Dolu bardak testinin (DBT) ağrılı diyabetik periferal nöropati (ADPN)’de kullanımını ve geçerliliğini test etmek.
📊
Key Findings & Data:Periferik nöropati tanısı muayene ve Douleur Neuropathique 4 (DN4) anketi kullanılarak gösterildi.
💡
Conclusion & Impact:Sonuç: Dolu bardak testi ADPN’de ağrı şiddetini belirlemede kullanışlı olabilir.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Amaç: Dolu bardak testinin (DBT) ağrılı diyabetik periferal nöropati (ADPN)’de kullanımını ve geçerliliğini test etmek. Gereç ve Yöntem: Bu kesitsel ve prospektif çalışmaya ADPN olan olgular alındı. Çalışma popülasyonunda periferal nöropati yapacak diğer nedenler ve kognitif yetmezlik dışlandı. Periferik nöropati tanısı muayene ve Douleur Neuropathique 4 (DN4) anketi kullanılarak gösterildi. Ağrı şiddeti tedavi öncesi ve sonrasında DBT ve Vizüel Analog Skala (VAS) ile değerlendirildi. Geçerlilik için DBT’nin VAS ile korelasyonuna bakıldı. Bulgular: Çalışmaya 43 (33 kadın, 10 erkek) olgu alındı. Ortalama yaş 61.9±8.25, ortalama hastalık süresi 13.02±7.6 yıldı. Tip I DM 2 (%4.7) olguda, Tip II DM 41 (%95.3) olguda mevcuttu. HbA1c düzeyi ortalama 8.9±1.9 mmol/mol’du. Ağrı şiddetinin değerlendirilmesinde kullanılan VAS ve DBT tedavi öncesi ve sonrası karşılaştırıldığında ortalama skorlar tedavi öncesinde 6.7±2.05, 66.35±23.2, tedavi sonrasında ise 4.6±2.2, 41.36±23.5 bulundu. Sonuçlar istatistiksel olarak anlamlıydı (p<0.001, p<0.001). Olgularda ortalama kontrol süresi 23.4 (minimum–maksimum: 15–30) gün oldu. Ağrı şiddet ölçeği DBT, tedavi öncesi ve sonrasında VAS ile yüksek korele bulundu (rs =0.86, p<0.001; rs =0.843, p<0.001). Sonuç: Dolu bardak testi ADPN’de ağrı şiddetini belirlemede kullanışlı olabilir.

Özet

Objectives: The aim of this study was to test the utility and validity of the full cup test (FCT) to assess the severity of pain in subjects with painful diabetic peripheral neuropathy (PDPN). Methods: Subjects with diabetic PDPN were enrolled for this prospective, cross-sectional study. Other causes of PDPN and subjects with cognitive impairment were excluded. The diagnosis of neuropathic pain was made using the results of a physical examination and the Douleur Neuropathique 4 questionnaire. Pain severity was assessed with a FCT and a visual analog scale (VAS) administered before and after treatment. The correlation of FCT with VAS was evaluated to examine validity. Results: A total of 43 (33 female, 10 male) subjects were included. The mean age was 61.9±8.25 years and the mean disease duration was 13.02±7.6 years. Type I diabetes mellitus (DM) was present in 2 (4.7%) subjects and Type II DM in 41 (95.3%) subjects. The mean glycated hemoglobin level was 8.9±1.9 mmol/mol. When the mean VAS and FCT scores were analyzed, the results were 6.7±2.05 and 66.35±23.2, respectively, pretreatment and 4.6±2.2 and 41.36±23.5 posttreatment, which were both statistically significant (p<0.001, p<0.001). The mean control period was 23.4 days (min–max: 15-30 days). The VAS and FCT scores in pretreatment and posttreatment demonstrated a high positive correlation (rs =0.86, p<0.001; rs =0.843, p<0.001). Conclusion: The FCT can be useful to detect pain severity in PDPN.

🔖

Cite This Article

SAY, B., ERGÜN, U., YILDIZ, A., ALPUA, M., ARIKAN, Ş. D., TURGAL, E. (2020). Ağrılı diyabetik periferal nöropatide dolu bardak testi ile ağrı şiddetinin belirlenmesi. Ağrı, Cilt: 32 - Sayı: 2, 85–90. https://ajindex.com/articles/142296

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Henschke N, Kamper SJ, Maher CG. The epidemiology and economic consequences of pain. Mayo Clin Proc 2015;90(1):139–47
  2. Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, et al. Assessment of pain. Br J Anaesth 2008;101(1):17–24
  3. Fillingim RB, Loeser JD, Baron R, Edwards RR. Assessment of Chronic Pain: Domains, Methods, and Mechanisms. J Pain 2016;17(9 Suppl):T10–20
  4. Paisley P, Serpell M. Improving pain control in diabetic neuropathy. Practitioner 2017;261(1802):23–6
  5. Ergün U, Say B, Ozer G, Yildirim O, Kocatürk O, Konar D, et al. Trial of a new pain assessment tool in patients with low education: the full cup test. Int J Clin Pract 2007;61(10):1692– 6
  6. Al-Samman AA, Al-Nuaime OS, Othma HA. Validity and Reliability of Full Cup Test in Pain Evaluation after Dental Surgery: A Comparison with Four Pain-Rating Scales in a Sample of Iraqi Patients. Journal of Oral and Dental Research 2016;1(1):2–7
  7. Jones RC 3rd, Backonja MM. Review of neuropathic pain screening and assessment tools. Curr Pain Headache Rep 2013;17(9):363
  8. Lund I, Lundeberg T. Aspects of pain, its assessment and evaluation from an acupuncture perspective. Acupunct Med 2006;24(3):109–17
  9. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39(2):175–91
  10. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain 1986;27(1):117–26
  11. Jensen M, Karoly P. Self-report scales and procedures for assessing pain in adults. In: Turk DC, Melzack R, editors. Handbook of pain assessment. 2nd ed. New York: Guilford Press; 1992. p. 135–51
  12. Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs 2005;14(7):798– 804
  13. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33(10):2285–93
  14. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004;5(2):133–7
  15. Pathak A, Sharma S, Jensen MP. The utility and validity of pain intensity rating scales for use in developing countries. Pain Rep 2018;3(5):e672
  16. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, mode